11
Dec
2018

OSI Veterans, and Versant Ventures, Unveil Startup To Fight Allosteric Resistance Mutations in Cancer

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Versant-backed Cimeio Gets $50M for Shielded Stem Cell Therapies
Versant, OrbiMed Invest $50M in Startup Inserting Genes in the Liver
Versant, RA Bet $47M on LENZ Therapeutics to Restore Near Vision in Middle Age
Stablix, Seeking to Stabilize Instead of Degrade Proteins, Raises $63M